María José Méndez-Vidal

Author

Also Known As

B. Pérez-Valderrama, Cristina Grávalos, M. J. Mendez-Vidal, M. J. Méndez-Vidal, M.J. Mendez-Vidal, M.J. Méndez-Vidal, Maria J. Mendez-Vidal, Maria J. Méndez-Vidal, Maria Jose Mendez-Vidal, Maria Jose Méndez-Vidal

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Reina Sofía Hospital Universitario Virgen del Rocío Instituto Maimónides de Investigación Biomédica de Córdoba Queen Mary University of London Institut Català d'Oncologia

About

María José Méndez-Vidal is an author at Hospital Universitario Reina Sofía specializing in oncology, medicine, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	413
2	Pharmacology	4	4	97
3	Health Sciences	3	3	51
4	Pathology	3	3	117
5	Diagnostic Sciences	2	2	37

María José Méndez-Vidal

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha, New England Journal of Medicine	2021	1.7K
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani, Annals of Oncology	2017	263
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study Toni K. Choueiri, Masatoshi Eto, Robert J. Motzer, The Lancet Oncology Pembrolizumab Versus SunitinibUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2023	149
A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). Thomas Powles, Alejo Rodríguez‐Vida, Ignacio Durán, Journal of Clinical Oncology UrologySurgical OncologyTumoral PathologyPd-l1 InhibitorGenitourinary Cancer	2018	90
A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). Thomas Powles, James Larkin, Poulam M. Patel, Journal of Clinical Oncology UrologyOncologyPd-l1 InhibitionPd-l1 InhibitorMedicine	2019	50
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms Viktor Grünwald, Thomas Powles, Masatoshi Eto, Frontiers in Oncology	2023	37
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program Daniel Castellano, Luis Aparicio, Emilio Esteban, Expert Opinion on Drug Safety	2014	28
SEOM clinical guideline for treatment of kidney cancer (2019) Begoña P. Valderrama, Cristina Suárez, Guillermo de Velasco, Clinical & Translational Oncology	2020	27
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial Bernadett Szabados, Alejo Rodríguez‐Vida, Ignacio Durán, European Urology Oncology UrologySurgical OncologyGenitourinary CancerMedicinePharmacotherapy	2021	27
SEOM clinical guideline for treatment of kidney cancer (2017) Enrique Gallardo, María José Méndez-Vidal, José Luis Perez‐Gracia, Clinical & Translational Oncology	2017	22

Page 1